Time to abandon CAR-T monotherapy for solid tumors

Limei Yin; Zhengwei Wan; Ping Sun; Ping Shuai; Yuping Liu

doi:10.1016/j.bbcan.2023.188930

Time to abandon CAR-T monotherapy for solid tumors

Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188930. doi: 10.1016/j.bbcan.2023.188930. Epub 2023 Jun 5.

Authors

Limei Yin¹, Zhengwei Wan¹, Ping Sun¹, Ping Shuai², Yuping Liu³

Affiliations

¹ Department of Health Management & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
² Department of Health Management & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China. Electronic address: shuaiping@med.uestc.edu.cn.
³ Department of Health Management & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China. Electronic address: 18981838972@163.com.

PMID: 37286147
DOI: 10.1016/j.bbcan.2023.188930

Abstract

In recent decades, chimeric antigen receptor T (CAR-T) cell therapy has achieved dramatic success in patients with hematological malignancies. However, CAR-T cell therapy failed to effectively treat solid tumors as a monotherapy. By summarizing the challenges of CAR-T cell monotherapy for solid tumors and analyzing the underlying mechanisms of combinatorial strategies to counteract these hurdles, we found that complementary therapeutics are needed to improve the scant and transient responses of CAR-T cell monotherapy in solid tumors. Further data, especially data from multicenter clinical trials regarding efficacy, toxicity, and predictive biomarkers are required before the CAR-T combination therapy can be translated into clinical settings.

Keywords: CAR-T; Combined therapy; Immunotherapy; Solid tumor.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy, Adoptive
Multicenter Studies as Topic
Neoplasms* / drug therapy
Receptors, Antigen, T-Cell / genetics
Receptors, Chimeric Antigen*
Tumor Microenvironment

Substances

Receptors, Chimeric Antigen
Receptors, Antigen, T-Cell